MEDIPOST’s R&D is focused on providing novel therapeutics for patients suffering from diseases and conditions with unmet medical need such as Osteoarthritis (OA) of the knee, Broncho-pulmonary Dysplasia (BPD) of prematurely born infants and Alzheimer's Disease (AD). MEDIPOST's flagship product CARTISTEM® for knee OA has been market approved with Biologics License Application (BLA) by the Ministry of Food and Drug Safety of Korea, as an allogeneic cell therapy product in 2012. CARTISTEM® has successfully completed P1/2 trial in the U.S. with 2-year F/U. PNEUMOSTEM® for the prevention of BPD with Orphan Drug Designation in Korea, U.S. and E.U., is currently under P2 trial in Korea and P1/2 trial in the U.S. has demonstrated meaningful clinical improvements in treated subjects both at 3 months and 2 years post-treatment. NEUROSTEM® for AD is in P2a trial in Korea after successfully completing first-in-human P1 trial in Korea with patients suffering from advanced mid-late stage AD.